Compugen Ltd. (CGEN)
Chart Events
Performance Outlook
| Previous Close | 8.66 |
| Open | 8.77 |
| Bid | 8.90 x 900 |
| Ask | 8.96 x 1100 |
| Day's Range | 8.63 - 8.96 |
| 52 Week Range | 7.10 - 19.90 |
| Volume | 835,832 |
| Avg. Volume | 1,483,088 |
| Market Cap | 684.009M |
| Beta (5Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.37 |
| Earnings Date | Feb 25, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.29 |
- Simply Wall St.
Did Compugen's (NASDAQ:CGEN) Share Price Deserve to Gain 94%?
The Compugen Ltd. ( NASDAQ:CGEN ) share price is down a rather concerning 39% in the last month. But over three years...
- PR Newswire
Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a review article titled "Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis" reviewing the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy. The peer-reviewed article, published in Cancer Discovery, a journal of the American Association for Cancer Research, was co-authored by Drew Pardoll, M.D., Ph.D., Professor of Oncology, Johns Hopkins University and Chairman of Compugen's Scientific Advisory Board.
- PR Newswire
Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Oppenheimer 31st Annual Healthcare Conference (virtual), on Tuesday, March 16, 2021 at 10:40 AM ET.
